Showing 1 - 10 of 17
estimated prices of these drug undergoing LOE fall with generic entry. Second, we estimate reduced form random effects models of … utilization subsequent to LOE. We observe substantial price erosion after generic entry; average monthly price declines appear to … entry, but this result appears to be largely driven by oral drugs. We discuss second-best welfare consequences of these …
Persistent link: https://www.econbiz.de/10010950850
The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of medication labeling changes on brand pharmaceutical products, and whether and what firms do to respond to increased information regarding the safety and efficacy...
Persistent link: https://www.econbiz.de/10009325511
comment on very recent developments concerning the entry of large retailers such as Wal-Mart into domains traditionally …
Persistent link: https://www.econbiz.de/10008531891
following initial generic entry and by 24 months to 65, in 2009 the comparable generic price indexes are 68 and 27, respectively … patent has expired. Across all nine therapeutic areas, at 24 months post-generic entry, the weighted mean reduction in …
Persistent link: https://www.econbiz.de/10008682661
low fixed costs and minimal entry barriers, both media-specific scale and scope economies are available and can be …
Persistent link: https://www.econbiz.de/10005248932
entry and exit behavior. We develop theoretical predictions based on the model of Lakdawalla and Philipson, in which for … using data for all U.S. hospitals from 1984 through 2000. Examining annual and regional entry and exit rates, for …-profit hospitals consistently have higher entry and exit rates than not-for-profits. Econometric modeling of entry and exit rates …
Persistent link: https://www.econbiz.de/10005085246
Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within specified time periods. In turn, the FDA was permitted to levy user fees on drug sponsors...
Persistent link: https://www.econbiz.de/10005084928
This paper reviews the literature devoted to studying markets for health care services and health insurance. There has been tremendous growth and progress in this field. A tremendous amount of new research has been done in this area over the last 10 years. In addition, there has been increasing...
Persistent link: https://www.econbiz.de/10009223314
The literature on mergers between private hospitals suggests that such mergers often produce little benefit. Despite this, the UK government has pursued an active policy of hospital merger. These mergers are initiated by a regulator, acting on behalf of the public, and justified on the grounds...
Persistent link: https://www.econbiz.de/10009368126
Much has been written about the seemingly less formal, more agile biotechnology industry and its extensive interactions with academia and startups, as well as its distinct scientific, manufacturing and regulatory profile. Employing a data base encompassing all 96 biologics and 212 small...
Persistent link: https://www.econbiz.de/10008635919